Skip to main content
A

AROVELLA THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · ALA ISIN · AU0000182784 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2026-04-26 Share Issue/Capital Cha…
Country AU Australia
Listing ASX ALA

About AROVELLA THERAPEUTICS LIMITED

https://www.arovella.com

Arovella Therapeutics Limited focuses on the development of innovative immunotherapies for cancer treatment. The company utilizes an invariant Natural Killer T (iNKT) cell therapy platform to create off-the-shelf treatments for blood cancers and solid tumors. Its lead candidate, ALA-101, features iNKT cells engineered with a Chimeric Antigen Receptor (CAR) to target CD19-expressing malignancies. Unlike traditional autologous CAR-T therapies, the iNKT platform is designed for allogeneic use, potentially reducing manufacturing complexity and increasing patient access. The company’s research extends to combining iNKT cells with other technologies to address a broader range of oncological indications, leveraging the innate and adaptive immune characteristics of iNKT cells to improve therapeutic outcomes.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - ALA 5 pages 16.7KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 3G notification regarding the issue of unquoted equity securities (options) by Arovella Therapeutics. It details the number of securities issued, issue date, and capital structure impact. This is an announcement of a share issue/capital change, matching our 'Share Issue/Capital Change' category.
2026-04-26 English
Proposed issue of securities - ALA 5 pages 17.0KB
Share Issue/Capital Change Classification · 1% confidence The document is an ASX Appendix 3B announcement detailing the proposed issue of 2,000,000 new options by AROVELLA THERAPEUTICS LIMITED, including security code, issue date, consideration, and Listing Rule compliance. This is clearly an announcement of a share issuance/capital change rather than a full report or earnings release. Thus it falls under Share Issue/Capital Change (SHA).
2026-04-22 English
Notice Received Under Section 249D Withdrawn 2 pages 155.6KB
Regulatory Filings Classification · 1% confidence The document is an ASX release announcing the withdrawal of a shareholder requisition notice under section 249D of the Corporations Act. It does not present financial results, management changes, dividends, capital changes, or detailed reports; it is simply a regulatory announcement regarding corporate governance procedure. It does not fit any specialized category (e.g., earnings release, dividend, M&A, director dealing, proxy materials), so it falls into the fallback “Regulatory Filings” category.
2026-04-22 English
Update Regarding Section 249D Notice 2 pages 156.2KB
Regulatory Filings Classification · 1% confidence The document is an ASX market release dated 22 April 2026 providing an update on a section 249D requisition notice under the Corporations Act. It does not announce any actual board appointments or management changes, nor capital transactions, dividends, or results; it simply informs the market of a regulatory/corporate governance matter that does not fit a more specific category. Therefore it is best classified under the general Regulatory Filings category (RNS).
2026-04-21 English
Arovella Presents Poster at AACR Annual Meeting 3 pages 2.2MB
Regulatory Filings Classification · 1% confidence The document is an ASX market release announcing that Arovella Therapeutics will present a scientific poster at the AACR Annual Meeting. It contains no financial results, no board or management changes, no capital raising, no dividend information, and no detailed financial report. It is a corporate event announcement and falls under general regulatory filings that do not fit into more specific categories. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-04-19 English
ALA Receives Additional R&D Tax Rebate of $0.28 Million 2 pages 205.9KB
Capital/Financing Update Classification · 1% confidence The document is an ASX release announcing Arovella Therapeutics’ receipt of an additional A$0.28 million R&D tax rebate, which bolsters its cash position. This is an update on the company’s financing activities rather than a dividend, share transaction, or full report. Therefore it fits the Capital/Financing Update category (CAP).
2026-04-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.